1例弥漫大B细胞淋巴瘤合并乙肝病毒感染患者的药学监护

Pharmaceutical care on a patient with DLBCL and HBV

1例30岁女性患者,因发现颈部肿物3个月,确诊恶性淋巴瘤3 d入院。入院后,给予CHOP方案化疗(环磷酰胺、表柔比星、长春新碱、泼尼松),21 d为一周期,化疗前给予恩替卡韦预防性抗病毒治疗,化疗期间给予还原型谷胱甘肽、异甘草酸镁保肝治疗。结合患者的基础情况,临床药师通过评估化疗方案的合理性,建议医生选用恩替卡韦预防性抗病毒,同时对化疗可能出现的不良反应提出药学监护和对患者进行用药教育,最大程度地提高药物的疗效,降低药物不良反应的发生率。患者最终顺利完成本周期治疗。

One case of 30-year-old female patient was hospitalized due to diagnosing with malignant lymphom for 3 days,and she was detected rumor for 3 months.Then she received CHOP chemotherapy（cyclophosphamide,epirubicin hydrochloride,vincristine,prednisone）,21 days as a cycle.Before the chemotherapy,she had taken entecavir as prophylactic antivirus therapy.During the chemotherapy she also received liver protection therapy such as reduced glutathione,magnesium isoglycyrrhizinate.According to disease situation of the patient,clinical pharmacists estimated the rationality of the chemotherapy and advised doctors to use entecavir as prophylactic antivirus therapy and took measures in case of adverse reaction.Pharmaceutical care and drug introduction to the patient was implemented to support the therapy perfectly and reduced adverse drug reaction as far as possible.At last,the patient recovered in the cycle therapy.